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Synopsis27
Objectives28
The oxazolidinone linezolid is an effective component of drug-resistant TB treatment, but use is limited29
by toxicity and the optimum dose is uncertain. Current strategies are not informed by clinical30
pharmacokinetic/pharmacodynamic (PK/PD) data, we aimed to aimed to address this gap.31
Methods32
We defined linezolid PK/PD targets for efficacy; free area under the time-concentration curve:33
minimum inhibitory concentration ratio (ƒAUC0-24:MIC) >119mg/L/hr and safety; free minimum34
concentration (Cmin) <1.38mg/L. We extracted individual-level linezolid PK data from existing studies35
on TB patients and performed meta-analysis; producing summary estimates of ƒAUC0-24 and ƒCmin for36
published doses. Combining these with a published MIC distribution, we performed Monte Carlo37
simulations of target attainment.38
Results39
The efficacy target was attained in all simulated individuals at 300mg q12h and 600mg q12h, but only40
20.7% missed the safety target at 300mg q12h versus 98.5% at 600mg q12h. Although suggesting41
300mg q12h should be used preferentially, these data were reliant on a single centre. Efficacy and42
safety targets were missed by 41.0% and 24.2% respectively at 300mg q24h, and 44.5% and 27.5% at43
600mg q24h. However, the confounding effect of between study heterogeneity on target attainment44
for q24h regimens was considerable.45
Conclusions46
300mg q12h linezolid dosing may retain the efficacy of the 600mg q12h licensed dosing with improved47
safety. Data to evaluate commonly used 300mg q24h and 600mg q24h doses is limited.48
Comprehensive, prospectively obtained PK/PD data for linezolid doses in drug-resistant TB treatment49
are required.50
Introduction51
TB remains a major global health problem, with approximately 10.4 million cases and 1.7 million52
deaths in 2016.1 Although worldwide incidence and mortality has slowly declined over the last 3053
years, the emergence of antibiotic resistant TB threatens further progress. MDR TB, defined as54
resistance to both rifampicin and isoniazid and rifampicin resistant (RR) TB (often diagnosed in settings55
where genotypic and or/phenotypic drug sensitivity testing (DST) to isoniazid is not available) aremore56
challenging to manage. There were 600,000 estimated cases of RR or MDR-TB worldwide in 2016 with57
success rates (cure and treatment completion) of approximately 50%.1Outcomes are particularly poor58
for MDR-TB patients with additional resistance to key second line-drugs (any fluoroquinolone and at59
least one second-line injectable agent); classified as XDR TB.1-460
Treatment of RR or MDR TB requires prolonged administration of multi-drug regimens including61
second-line antibiotics with reduced efficacy and higher toxicity than first-line drugs.5,6 High rates of62
clinical failure, compounded by a rising incidence of second-line drug resistance and regular63
treatment-limiting toxicities have prompted increased use of the oxazolidinone, linezolid, to design64
adequate regimens. Although currently licenced for use in Gram positive bacterial infections, linezolid65
has bactericidal activity against Mycobacterium tuberculosis and has been repurposed as a class C,66
core MDR TB drug.5-8 The standard dose for treatment of Gram positive infections in adults is 600mg67
twice daily (q12h) for a maximum of 28 days, but the duration required for MDR or RR TB treatment68
is much longer. Whilst addition of linezolid to RR or MDR-TB treatment can improve outcomes,69
prolonged administration is often limited by toxicity.9-11 Myelosuppression (particularly70
thrombocytopenia) is common. Peripheral and optic neuropathy, hepatotoxicity, lactic acidosis and71
hypoglycaemia are rarer adverse effects but can be serious (and in the case of neuropathies,72
irreversible) when they occur.12,13 Toxicity from linezolid in TB treatment regularly necessitates dose73
reduction, but the optimal safe, efficacious dose remains unknown.74
In healthy volunteers, the plasma pharmacokinetics (PK) of linezolid are 31% protein binding, excellent75
tissue penetration, maximum plasma concentration (Cmax) of 15-27 µg/mL, time to maximum76
concentration (Tmax) of 0.5-2 hours and a half-life of 3.4-7.4 hours.14 However, the PK profile varies77
between patient populations, for instance critically ill patients have increased levels of free linezolid78
associated with hypoalbuminaemia, reduced renal clearance with low body weight and markedly79
increased inter-patient variability.15-17 The PK profile of linezolid in TB patients is poorly characterised80
and dosing has never been informed by an analysis of how successfully different doses might attain81
target pharmacokinetic/pharmacodynamic (PK/PD) parameters for efficacy and safety.82
We defined PK/PD efficacy and safety targets for linezolid in clinical TB treatment from the literature83
and conducted a meta-analysis of published data collected during therapy to generate summary84
estimates of key secondary PK parameters; free area under the time-concentration curve (fAUC0-24)85
and free minimum concentration (fCmin). Finally, we simulated attainment of the PK/PD targets on the86
basis of the summary estimates obtained and a published MIC distribution.87
Materials and methods88
Identifying PK/PD targets89
There are no universally accepted PK/PD targets to maximise efficacy and safety of linezolid in TB90
therapy. In general, the AUC0-24:MIC ratio is the PK/PD parameter most predictive of the activity of91
anti-tuberculous drugs.18 For linezolid, some hollow fibre infection model (HFIM) and ex-vivo blood92
culture data suggest that the proportion of the dosing interval for which concentrations exceed the93
MIC (T>MIC) may influence efficacy against M.tuberculosis, but more extensive in vitro, murine and94
human early bactericidal activity (EBA) studies support AUC0-24:MIC as the main parameter of95
interest.19-22 HFIMs corroborate clinical data from Gram positive infections which suggest an efficacy96
target of fAUC0-24:MIC >100-119mg/L/hr. We used the more conservative threshold of 119mg/L/hr as97
the efficacy target for our simulations.20, 23-2698
Linezolid clinical toxicity studies are mainly limited to less than 28 days. Given the cumulative nature99
of linezolid toxicity, these cannot inform PK/PD targets during prolonged therapy. Amongst the PK100
parameters, most evidence exists for a relationship between Cmin and toxicity.15,27 In the only clinical101
study conducted in the context of prolonged TB therapy, all patients with Cmin>2mg/L, developed an102
adverse event (principally thrombocytopenia) versus less than half of those with Cmin <2mg/L.28We103
used fCmin<1.38mg/L (equivalent to a total Cmin of 2mg/L) as the safety target for our simulations.104
Systematic review and meta-analysis of linezolid PK data during TB therapy105
To produce summary estimates for fAUC0-24, and fCmin for all dosage regimens currently described, we106
extracted data from all randomised controlled trials or observational studies published in the English107
language on adult (>16 years) TB patients (any resistance pattern) where linezolid was administered108
for at least three days and serum concentrations (at least Cmax and/or Cmin or AUC0-24) were assessed109
using HPLC and reported disaggregated by dose. Single study data for more than one dosage110
(milligrams, mg) in the same patient was permitted, so long as a minimum one week washout period111
had taken place. To ensure focus on dosages where a basic minimum of PK evidence was available,112
we excluded dosages where less than 10 total patients, across studies, were identified.113
We searched MEDLINE (1990 to December 2017), EMBASE (1990 to December 2017), The114
International Union Against Tuberculosis and Lung Disease conference abstracts and American115
Thoracic Society conference abstracts, using the search terms; Tuberculosis AND (Linezolid OR116
Oxazolidinone* OR PNU-100766 OR U-100766). This search was supplemented by hand searching the117
reference lists of identified studies and selected reviews. Authors were contacted to clarify missing or118
inconsistent data and, if needed, for individual level PK data.119
We constructed time-concentration curves to calculate fAUC0-24 using the trapezoid rule.29 fAUC0-24120
and fCmin data were normally distributed, hence the meta-analysis and Monte Carlo simulations used121
means and standard deviations (SDs) as summary descriptors for all studies. If PK results were not122
otherwise available, data were extracted from published graphs using digitising software (Plot123
Digitizer, version 2.5.0). Meta-analysis was conducted using the metafor package in R for Windows,124
version 3.2.2 to provide a summary mean fAUC0-24 and fCmin, 95% confidence interval and I2 statistic125
for heterogeneity. To emphasise the importance of the heterogeneity of the data, we allowed meta-126
analysis at any level of heterogeneity.127
Monte Carlo simulation128
Using the summary PK estimates identified, we modelled PK/PD target attainment from 100,000129
simulated patients at each dose for which data were available. Wild-type linezolid MIC distributions130
were derived from previously published data in drug sensitive TB (DS-TB). Briefly, this distribution131
describes the linezolid MIC results from the isolates of 78 consecutive TB patients in Sweden who had132
no resistance to all first-line and major second line drugs. The linezolid MICs ranged from 0.125 to133
0.5mg/L (comprising one isolate with MIC 0.125, 61 isolates with MIC 0.25 and 16 isolates with MIC134
0.5 mg/L respectively).30 There are no published linezolid MIC distributions in RR or MDR TB. However135
MIC values covering 50% and 90% of isolates (MIC50 andMIC90) in MDR TB have been reported as 0.25136
– 0.5 and 0.25 – 1µg/ml respectively, which is consistent with the wild type distribution we used.31-33137
We assumed a log normal distribution for fAUC0-24, fCmin and fAUC0-24:MIC. We simulated fCmin, fAUC0-138
24 and MIC for 100,000 virtual patients in R for Windows. The pnormGC function in the tigerstats139
package was used to calculate and produce plots of the attainment of the PK/PD targets. We treated140
the fAUC0-24 and MIC variables as independent of one another. For doses with high levels of141
heterogeneity (I2 >50%) we performed a sensitivity analysis; imputing each study at these doses into142
the simulation independently to assess the impact of this heterogeneity on target attainment.143
Results144
Meta-analysis of existing linezolid pharmacokinetic data in tuberculosis therapy145
1602 citations were screened and eight studies were suitable for meta-analysis. Reasons for inclusion146
and exclusion are provided in the PRISMA diagram (Figure 1). Included studies are summarised and147
disaggregated by dose, in Table 1. We obtained individual participant level data for all of these studies.148
Data were combined using a random effects model; forest plots are provided in Figures 2 and 3.149
Summary fAUC0-24and fCmin mean and SDs are provided for each dose in Table 1.150
At the 300mg q12h and 600mg q12h doses, PK sample collection was intensive across five studies and151
heterogeneity was lower (I2<50% for fAUC0-24 and fCmin at both doses). However, data at these doses152
were reliant on a single centre (three out of five studies at both doses). Summary estimates for the153
300mg q24h and 600mg q24h doses relied on sparse sampling from only two studies and results154
demonstrated a high degree of inter-study heterogeneity (I2=89-91% for fAUC0-24 and 67-99% for155
fCmin).156
Monte Carlo simulation of the attainment of PK/PD targets157
Using the summary estimates of fAUC0-24 from the meta-analysis and the wild type MIC distribution158
we assessed attainment of fAUC0-24:MIC >119mg/L/hr for each dose in a simulated population of159
100,000 individuals (Figure 4).30 The efficacy target was attained in all simulated individuals at the160
300mg q12h and 600mg q12h doses. The target was not attained for 41.0% and 44.6% of simulated161
individuals at the 300mg q24h and 600mg q24h doses, respectively. Given the high heterogeneity162
between studies at the 300mg q24h and 600mg q24h doses, we performed a sensitivity analysis by163
imputing each study at these doses into the simulation independently. In this analysis, the efficacy164
target was attained by all individuals in both studies at both doses, (Figure 5).165
Using the summary estimates for fCmin from the meta-analysis we simulated the attainment of fCmin166
<1.38mg/L for each dose (Table 2). More than 98% at 600mg q12h, and at least 20% of individuals at167
all doses failed to achieve this target. Again, because of heterogeneity between studies at the 300mg168
q24h and 600mg q24h doses, we performed a sensitivity analysis, imputing the individual studies at169
these doses into the Monte Carlo simulations. Differences between attainment of the safety target170
when imputing studies individually were substantial (64.19% for Koh et al versus 94.95% for Lee et al171
at 300mg q24h and 97.87% for Dietze et al versus 33.68% for Lee et al at 600mg q24h).172
173
Discussion174
Linezolid is an important drug in the management of RR and MDR TB but its use is often limited by175
toxicity, prompting consideration of reduced dosing strategies. Our analysis is the first to provide176
summary PK data and simulate PK/PD target attainment to inform dose selection in clinical practice177
and clinical trials. We meta-analysed published data to generate summary estimates of plasma ƒAUC0-178
24:MIC and ƒCmin at different doses of linezolid, then performed Monte-Carlo simulations based on179
these summary estimates to quantify attainment of putative PK/PD targets for efficacy and safety.180
Current PK data on linezolid in TB patients are limited. Eight clinical studies, using four dosing181
strategies, were available for our analysis. These used variable, sometimes sparse, sampling schedules182
resulting in considerable heterogeneity between studies when meta-analysing data at 300mg q24hr183
and 600mg q24hr doses. Consequently, summary estimates for ƒAUC0-24 and ƒCmin at these doses are184
accompanied by wide standard deviations. Sensitivity analyses, based on separate simulations for185
each study at these doses shows that attainment of efficacy and safety targets is strongly influenced186
by inter-study heterogeneity. Consequentially, existing data do not definitively support any one dosing187
strategy and further prospective linezolid PK studies, ideally using standardised sampling schedules,188
are required. Nonetheless important observations can be made from our analysis.189
A linezolid dose of 1200mg/day has recently been used alongside bedaquiline and pretomanid as part190
of the Nix-TB trial regimen (NCT02333799) on the basis of continued dose-response in an early191
bactericidal activity study. Preliminary results suggest that this regimen achieves good clinical192
outcomes but 71% of patients have at least one dose interruption due to toxicity.40 Prior PK data are193
unavailable for 1200mg q24hr, so we meta-analysed data for 600mg q12h. 100% attainment of the194
efficacy target but <1% attainment of the safety target in our simulations is consistent with the195
emerging Nix-TB results of high efficacy but problematic side-effects. The ZeNix trial (NCT03086486)196
will test the efficacy and toxicity of 600mg q24hr versus 1200mg q24h of linezolid within this regimen.197
In search of a less toxic dosing regimen, prior meta-analyses support clinical efficacy of linezolid198
600mg/day or lower.9,10 One lower dose linezolid strategy is 300mg q12h, for which our simulations199
described 100% efficacy target attainment and failure to meet the safety target in only 20.7% of200
patients. These results support preferential use of this dose. However, as many patients were from a201
single centre, generalisability of this finding will depend on prospective studies in other populations.202
Alternatively, once daily dosing at 600mg q24h is often advocated because of greater convenience.203
Our simulations were based on ameta-analysis of two studies and described only 55.5% efficacy target204
attainment and failure to meet the safety target in 27.5% of simulated patients. Assuming a half-life205
of 5 hours, accumulation ratios of 1.03 and 1.23 are expected for q24h and q12h linezolid dosing206
regimens respectively, so the AUC0-24 for linezolid may be up to 20% higher for 300mg q12h than207
600mg q24h and this may have contributed to higher efficacy target attainment with the 300mg q12h208
dose. However, as our sensitivity analyses show that heterogeneity of study results strongly influenced209
attainment of efficacy and safety targets in simulations at 600mg q24h, further studies are required210
before judgement can be passed on this dosing strategy.211
A lower linezolid dose of 300mg q24h is used clinically, particularly in patients who have already212
reported side-effects. We found limited PK assessment of this strategy. In simulations based on meta-213
analysis of data from two studies, efficacy target attainment and failure to meet the safety target were214
similar to 600mg q24h at 59.0% and 24.5% respectively. This demonstrates that effective therapy is215
possible at 300mg q24h for some individuals but that linezolid will cause some toxicity irrespective of216
dose alteration. As with 600mg q24h, the high degree of heterogeneity in study results at this dose217
complicates these analyses and underlines the need for prospectively gathered PK data at this218
clinically important dose.219
Overall, these data suggest that future clinical trials containing linezolid should evaluate multiple220
dosing regimens, and that trials of alternative oxazolidinones which retain efficacy with lower toxicity221
are urgently needed. For instance, sutezolid has demonstrated greater antimycobacterial activity than222
linezolid in a whole blood culture model, treatment shortening in a mouse model and sustained EBA0-223
14 in humans (which have not been demonstrated with linezolid), whilst demonstrating a more224
favourable PK/PD profile in terms of likely mitochondrial inhibition and apparently lower rates of225
toxicity in small, limited duration, human studies.8,41,42 Trials of cyclical linezolid courses to maximise226
efficacy and then allow cumulative toxicity to abate should be considered; we could not assess this227
strategy in our analysis. Intermittent dosing strategies have been proposed, whereby a higher linezolid228
dose (e.g. 1200mg) is given on alternate days to ensure efficacy target attainment but allow longer229
periods of safety target attainment.43 Our data provide supportive evidence that the summary230
estimate of AUC0-24 for 600mg q12h approximates a doubling of the 300mg q12h and 600mg q24h231
summary estimates for AUC0-24, but existing data do not allow us to comment on any improvements232
in safety target attainment with intermittent dosing. Whilst revised dosing strategies are being233
established, therapeutic drug monitoring (TDM) may have a role to maximise attainment of efficacy234
and safety targets for individual patients. Moreover, population PK models indicate that renal235
clearance accounts for up to 70% of inter-individual variation in linezolid levels suggesting potential236
benefit from initial dosing based on renal function, formulae for which have been proposed.13,44237
In addition to highlighting the need for more PK data, this study has several limitations. Our putative238
PK/PD efficacy and safety targets may not be precise. The efficacy target was based on HFIM data in239
the absence of any measurement validated against clinical outcomes. The safety target was derived240
from one clinical study from Asia, with thrombocytopenia as the principal outcome.28 This may not be241
representative of overall linezolid toxicity. More robust linezolid PK/PD targets for TB therapy require242
prospective clinical evaluation. Secondly, the wild-type linezolid MIC distribution used for fAUC:MIC243
simulations was from drug-sensitive TB because there are no published linezolid MIC distributions in244
RR or MDR TB. However, MIC50 and MIC90’s from these populations are in broad agreement with the245
wild type data.31-33 Additionally, the MIC testing for this distribution was conducted using Middlebrook246
7H10 media and may not be representative of the distribution obtained using alternative media.30247
Thirdly, development of linezolid resistance during therapy is an important outcome and may be a248
particular risk at lower doses.45 We have not yet simulated the attainment of resistance prevention249
PK/PD targets and future studies should seek to do this.250
In conclusion, despite increased use of linezolid in RR and MDR-TB treatment, there remains no251
consensus on optimal safe dosing. Current PK/PD data are insufficient to confidently provide a252
solution. Compared to the standard dose of 600mg q12h, a dose of 300mg q12h may retain efficacy253
with lower toxicity. Prospective clinical studies are required to test this proposition and to better254
assess once daily dosing strategies.255
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385
Figure 1: PRISMA flowchart of included and excluded studies for the meta-analysis of existing linezolid386
pharmacokinetic (PK) data in tuberculosis (TB) therapy387
388
Figure 2: Forest plot of included studies for meta-analysis of free area under the time-concentration389
curve (fAUC0-24) at different doses of linezolid. Sampling time points in brackets not assessed for all390
patients391
392
Figure 3: Forest plot of included studies for meta-analysis of free minimum concentration (fCmin) at393
different doses of linezolid. Sampling time points in brackets not assessed for all patients394
395
Figure 4: Probability density distributions of the attainment of linezolid fAUC0-24:MIC >119µg/ml/hr396
(vertical line) in a Monte Carlo simulation of 100,000 patients at different doses of linezolid, based on397
a published MIC distribution and summary AUC0-24 from a meta-analysis of published data.398
399
Figure 5: Probability density distributions of the attainment of linezolid fAUC0-24:MIC>119µg/ml/hr400
(vertical line) in a Monte Carlo simulation of 100,000 patients at different doses of linezolid, based on401
a published MIC distribution and summary AUC0-24 in a sensitivity analysis imputing individual studies402
at the 300mg q24h and 600mg q24h doses separately403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
Table 1: Meta-analysis of fAUC0-24and fCmin for different doses of linezolid in tuberculosis therapy419
300 q24h Sampling
timepoints (hrs)
n fAUC 0-24
mean
fAUC 0-24
SD
fCmin fCmin SD
Koh et al,
200934
0,2 10 113.56# 49.33# 1.45ǂ 0.98ǂ
Lee et al, 201211 0, 2 28 64.91* 22.59* 0.87* 0.61*
Summary 86.92 149.27 1.09 1.73
300 q12h Sampling
timepoints (hrs)
n fAUC 0-24
mean
fAUC 0-24
SD
fCmin fCmin SD
Bolhuis et al,
201535
0,1,(2),3,4,(5),(8),1
2
21 95.45* 41.60* 2.23* 1.47*
Bolhuis et al,
201336
0,1,2,3,4,8 5 77.27* 32.05* 1.73* 1.40*
Alffenaar et al,
201037
0,1,2,4,8,12 5 80.51* 32.22* 1.37* 0.66*
Alffenaar et al,
201038
0,1,2,4,8,12 8 74.53* 26.54* 1.20* 0.85*
Vu et al, 201239 0,1,2,3,4,8 2 71.58* 2.49* 0.93* 0.34*
Summary 77.82 31.46 1.18 0.94
600 q24h Sampling
timepoints (hrs)
n fAUC0-24
mean
fAUC 0-24
SD
fCmin fCmin SD
Dietze et al,
200821
0,1,2,4,8,12 10 66.10* 18.24* 0.05* 0.14*
Lee et al, 201211 0,2 38 124.75* 48.74* 1.88* 1.19*
Summary 95.18 203.16 0.96 6.34
600 q12h Sampling
timepoints (hrs)
n fAUC0-24
mean
fAUC0-24
SD
fCmin fCmin SD
Bolhuis et al,
201535
0,1,(2),3,4,(5),(8),1
2
8 134.67 64.17 3.48 2.97
Dietze et al,
200821
0,1,2,4,8,12 9 172.75* 61.99* 3.03* 2.00*
Alffenaar et al,
201037
0,1,2,4,8,12 4 169.87* 70.53* 3.82* 2.71*
Alffenaar et al,
201038
0,1,2,4,8,12 8 180.13* 48.21* 3.48* 1.85*
Vu et al, 201239 0,1,2,3,4,8 6 156.31* 59.51* 4.33* 2.50*
Summary 165.05 58.5 3.48 2.23
SD = standard deviation, fAUC0-24 = free area under time-concentration curve (mg/L), fCmin = free
minimum concentration (mg/L), timepoints in brackets () not sampled for all participants, n =
number of participants sampled, n/a = data not available. Colour coding represents source of
data: ǂ from paper, * from individual level data provided by authors, # from graph digitising
software
420
421
Table 2: Percentage (%) of 100,000 simulated patients below a safety threshold; fCmin <1.38µg/ml422
based on summary pharmacokinetic data for different linezolid doses423
Dose % below <1.38µg/ml
300mg q24h 75.47%
300mg q12h 79.30%
600mg q24h 72.53%
600mg q12h 1.42%
424
